Latest AstraZeneca News | Page 6 | The National Tribune

5 Apr 2023 10:12 am AEST

Sydney supports extension of educational equity program in schools

3 Apr 2023 4:21 pm AEST

Ultomiris recommended for approval in the EU by CHMP for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)

3 Apr 2023 5:21 am AEST

GPs more likely to undercharge than overcharge Medicare

30 Mar 2023 4:09 pm AEST

License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed

27 Mar 2023 4:15 pm AEST

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

27 Mar 2023 2:30 pm AEST

TGA Product Information safety updates 27 March

23 Mar 2023 5:12 pm AEST

Calquence granted first regulatory approval in China for adults with previously treated mantle cell lymphoma

17 Mar 2023 12:30 am AEST

Antibody fragment-nanoparticle therapeutic eradicates cancer

10 Mar 2023 5:06 pm AEST

AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge

9 Mar 2023 5:12 pm AEST

Tagrisso demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

9 Mar 2023 5:12 pm AEST

Imfinzi significantly improved event-free survival in AEGEAN Phase III trial for patients with resectable non-small cell lung cancer

6 Mar 2023 5:06 pm AEST

Enhertu showed clinically meaningful and durable responses across multiple HER2-expressing tumour types in DESTINY-PanTumor02 Phase II trial

3 Mar 2023 12:06 am AEST

Update on US regulatory review of Lynparza in combination with abiraterone for metastatic castration-resistant prostate cancer

8 Feb 2023 3:21 pm AEST

Haven’t had COVID or a vaccine dose in the past six months? Consider getting a booster

31 Jan 2023 9:24 am AEST

TGA Product Information safety updates 31 January

22 Dec 2022 2:48 pm AEST

How common are severe side effects from COVID vaccines? And how are they detected?

21 Dec 2022 10:24 am AEST

TGA Product Information safety updates 21 December

14 Dec 2022 3:09 am AEST

Preoperative immunotherapy for mesothelioma shows favorable outcomes

9 Dec 2022 11:03 pm AEST

Datopotamab deruxtecan showed promising responses as monotherapy and in combination with Imfinzi

9 Dec 2022 9:03 am AEST

Datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated HR-positive

8 Dec 2022 11:45 pm AEST

Camizestrant significantly delayed disease progression in advanced ER-positive breast cancer

8 Dec 2022 11:33 pm AEST

Capivasertib plus Faslodex reduced risk of disease progression or death by 40% versus Faslodex

8 Dec 2022 2:24 pm AEST

TGA Product Information safety updates

7 Dec 2022 11:33 pm AEST

Enhertu achieved statistically significant overall survival, reducing risk of death by 36% vs. trastuzumab emtansine

30 Nov 2022 5:03 pm AEST

AstraZeneca showcases strength of haematology portfolio and pipeline across multiple hard-to-treat conditions

30 Nov 2022 4:33 am AEST

AstraZeneca announces sale of its West Chester, Ohio manufacturing site

29 Nov 2022 5:06 pm AEST

AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy

22 Nov 2022 5:06 pm AEST

AstraZeneca aims to redefine breast cancer care with new data across treatment spectrum at SABCS 2022

17 Nov 2022 5:15 am AEST

Thousands of Tasmanian devils are dying from cancer – but a new vaccine approach could help us save them

15 Nov 2022 11:15 pm AEST

AstraZeneca ranked in top three in Access to Medicine Index

14 Nov 2022 5:15 pm AEST

Enhertu recommended for approval in EU by CHMP for patients with previously treated HER2-positive advanced gastric cancer

14 Nov 2022 5:09 pm AEST

Imfinzi plus chemotherapy recommended for approval in EU by CHMP as first immunotherapy regimen for advanced biliary tract cancer

14 Nov 2022 5:03 pm AEST

Lynparza in combination with abiraterone recommended for approval

11 Nov 2022 5:09 pm AEST

AstraZeneca expands global footprint in rare disease with availability of first Alexion rare disease therapy for patients

11 Nov 2022 5:03 pm AEST

Imfinzi and Imjudo with chemotherapy approved in US for patients with metastatic non-small cell lung cancer

11 Nov 2022 12:18 pm AEST

Previous COVID infection may not protect you from new subvariant wave. Are you due for booster

11 Nov 2022 5:03 am AEST

Previous COVID infection may not protect you from new subvariant wave

10 Nov 2022 5:03 pm AEST

Year-to-date and Q3 2022 results

9 Nov 2022 5:06 pm AEST

PT027 recommended by FDA advisory committee as new rescue treatment for asthma

8 Nov 2022 3:03 am AEST

Farxiga improved symptom burden and health-related quality of life

6 Nov 2022 12:03 am AEST

AstraZeneca presents data at ASN Kidney Week 2022 reinforcing urgent need for early screening of chronic kidney disease and benefits

4 Nov 2022 5:03 pm AEST

Beyfortus approved in EU for prevention of RSV lower respiratory tract disease in infants

2 Nov 2022 5:09 pm AEST

AstraZeneca funds R&D Postdoctoral Challenge finalists

1 Nov 2022 5:03 pm AEST

Vaxzevria receives full Marketing Authorisation in EU for prevention of Covid

31 Oct 2022 7:03 pm AEST

AstraZeneca advances scientific leadership in cardiovascular and renal diseases with over 60 abstracts collectively

26 Oct 2022 4:09 pm AEST

Camizestrant significantly improved progression-free survival in advanced ER-positive breast cancer

26 Oct 2022 4:03 pm AEST

Capivasertib Phase III trial met primary endpoints

25 Oct 2022 4:06 pm AEST